`
`tifi
`
`: Env
`
`Home News & Media Press Releases
`
`U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Ernbolisrn (PE). and for
`the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
`
`> nmAMH.IHm
`> Egfikmmrmdsgrwyhkphnyfieyaflfindlryarflmfiymualmqninhwhhhunflflflfld
`ThI.Ils1hy,AugIst21_201lc- 131pII'IEDT
`BristoFMyersSqui:Ib Company(NYSE:BMY)and PfizaIm(NVSE:PFBmdayumm1medfimUSFoodmdm1gAdrirBhafim(FDA)h5apprweda
`SupplementliNevtDrugAppIomion(sll)A)forERpisforl‘heueannemofDWmidPEmIdfuunreducfiminmerBkofmamaItmflmdPEfoImuiiginitial
`lherq)y.CoInbiIed.UVl'andPEamhumIosWEItB5&rmedmmauyyem,apprafinItely9(n,m)0NnukaBamafiededbyDVTu1dPE
`
`"weaepleuseduntaiyuisismwmdhueasmefiecfiveueuummopumfmUvrmdve'saidooighsMmimMn,Headofspedultyoeveiopmem.
`&EtoPMyasSqIiw.'H?pSofiusmddnsig,mm|fimmquhfionmsfig.mfldo5Immqimfluuseofaparemeni¢I1ticoagu|antorbridj1gi:hriIg
`'IIitimioll"
`
`‘lIW'I'_wIIi:hmay|eadtoPE.aIIbeaseliouslne¢ica|aandiion,withPEre¢pii1ginrnediatenie¢icdal1emioIIfarheannent0r|oeaVfEIuIsoa:uned,
` ' 33percentofpmIems' aeotriskdarea:ra$ewiliI10yca5.'§fidSteveRarmm.seIiuvicepresdun.' HcodofMedia'nesDevelopment
`Groipforfilobdmrwmfin MhrlmTM&BmFwmSqIflmflPhHa&mBmnmmmm£vfigirrpmmmmmmmwwsm
`potientsaidpllysicians‘
`
`Thefullhesaiaiigmbnmfimhflfilfihdflsflmmwafigfumuueaudrfldmmfimkauminpfiaummwmmzqfimmmmfimfi
`(mdforfl|eiIaeas¢dnskofepi<hva|orspiia|lienutmI:.wlidinuyaxuekmg-tummpernummpardy§shpafiansusiIgEqu3mduMagoi1gspixfl
`epidurdaieslhesiaorspiulpilricuxe.
`
`E¢:Bhueasesfl|erBkofbleedhgaxlmnan5esaiwspotaIidyfam|.bkcdhgPleaseseelhecompletentmedwanliigsmdcnidiitxuflhnpomrnsnfety
`lnfonnationilthispresslelease.
`
`TheFDAq.ipruNaloffirpsforlhetreallnemofflvfaidPfiandfud¢redIxtiinhflIerSkofmmnemDWudPEfoIowingirifidflIaapy,Bbasedmdam
`fromlheg|obaIAMPLIFVandAMPl.lFV-EXTstu¢ies
`
`11IeAMPlJFYm|dy,aru1doaiz\ed,daIIIle-bEidtrid.wasdesigIIedmdeIlmr5mtelheelfiuxy¢idsafelyofEquisfwflieueahnemofUVTmIdPEmid
`iid||dedpmiemsw'IiIcol|firInedsyIn|1nrru:ticD\frorPE(2.flBfaEfl]Iisam2fi35fustnduddmrgwhidImsiflfiaImmq)ui|htmmmfordkast
`fivedaysmverlappedbywarfaiifllelqvyflntenittimalflorvluizadkatia(lNR)range2.0-3.0]ordlyforsixnIomi|s).
`
`lntheAMPl1FYstudy_Eiqlislonigtwicetlilyforoiieweekfolmuedbysmgtwinednilyfmfixmuifludflnmsumndefficncycmnpambkmstadmdofure
`i1treatiIg[Nl'andEpdirnhrflnwhuqeffiaKymmp§mai¢fimdruuImmsyrqmImkWEuVE-rdaudkmlajfiu2.7%,re|aliverisk.
`0.81:: 9596confdence'nte|v|:I [G1, 0_60bo1.18:P-vaIue<0_ll)01 for non‘nfeI'iarity)_
`
`Eimafidmmnrmednpaiuiyhflupnmuynidyampoindlmprflxfingvaussnufluddmm(0.6%vs.1896.re|ativerisk0.31:9S%Cl,0.17to0.5S;
`P<0_0001 Ma;orblee¢irIgiuusdef‘n¢dasdiriuIyavertblee¢iIgfliatwusancornpmiedbyoneornusreofthefolkvwirlgadeaaaseinthe
`hernogobinleveld2gldlormore:atnmsfusiondmoanmemhsdpadzdmdfloododkflufilgflmomntdhdhcstauofflnfohwiigaiiai
`
`Fud:2m1Mqmffiyaflp&min&mAMHJHmidy.0waamm5firci1hIyMwunrmmqubludig(CRNM)werefewainEquisrlnaledpatimts
`mmpaedmstaridadofmreuveamdpatients(3.996vs_8.096).Cflflmwasdefindasmatbhediigflmtddruxrmetflreaierhfixnmyxbleednghtims
`assoahtsadwithamecicdilmmfimnmimtwfllaflmfimjlmnpmndflummymgwdfiafimailpfimmhmnfigunmflamvfis.
`lnAMPl.IFV,lherisoomim:ationnI:eduelnI:l¢¢dingeveIiswas0.736inlheHqId9ne<t¢dpafiunsmmparedm1_7%inumxnpariIIwufuirueatcdpafiu'ns
`
`Abo
`
`flp1Mww_;fizer_cunIneusIpress-releaseIpess-release-delziIIu_s_ih_qiproves_eliqis_q:ixa1m_fu'_lhe_lredrneri_d_deep_v6n_llI'ornbosis_dvl_a|d
`
`1/4
`
`Page 1 of 1
`
`SENJU EXHIBIT 2300
`
`LUPIN v. SENJU
`
`IPR20l5—0l105